mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)

American Journal of Hematology

Volumn 83, Issue 8, 2008, Pages 688-689

  Holtan, Shernan G ^a   Porrata, Luis F ^a   Colgan, Joseph P ^a   Zent, Clive S ^a   Habermann, Thomas M ^a   Markovic, Svetomir N ^a  

^a Graduate School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMMUNOGLOBULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; RAPAMYCIN; RITUXIMAB;

ADULT; AGED; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LETTER; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

AGED; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROTEIN KINASES; SIROLIMUS; TREATMENT FAILURE; VIREMIA;

EID: 49149087079     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21216     Document Type: Letter

References (11)

1. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005;23:7574-7582.
2. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
3. Brengel-Pesce K, Morand P, Schmuck A, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol 2002;66:360-369.
4. Krause I, Wu R, Sherer Y, et al. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - A potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002;12:133-139.
5. Abedi MR, Linde A, Christensson B, et al. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. Int J Cancer 1997;71:624-629.
6. Schaar CG, van der Pijl JW, van Hoek B, et al. Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder. Transplantation 2001;71:47-52.
7. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of post-transplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000;97:4285-4290.
8. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004;18:446-449.
9. Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003;16:202-206.
10. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003;63:4472-4480.
11. Vaysberg M, Balatoni CE, Nepomuceno RR, et al. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 2007;83:1114-1121.